These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30966822)

  • 41. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
    Bertero E; Prates Roma L; Ameri P; Maack C
    Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
    Chen HY; Huang JY; Siao WZ; Jong GP
    Cardiovasc Diabetol; 2020 Jun; 19(1):73. PubMed ID: 32503541
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 44. SCORED and SOLOIST: the next scores for SGLT2 inhibitors.
    Bauersachs J
    Cardiovasc Res; 2021 Mar; 117(4):e49-e51. PubMed ID: 33439963
    [No Abstract]   [Full Text] [Related]  

  • 45. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 46. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
    Pagidipati NJ; Lopes RD
    J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
    [No Abstract]   [Full Text] [Related]  

  • 47. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure.
    Sharma A; Ezekowitz JA
    Can J Diabetes; 2020 Feb; 44(1):103-110. PubMed ID: 31630988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship.
    Wilkinson MJ; Zadourian A; Taub PR
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S3-S11. PubMed ID: 31741438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Class effect for SGLT-2 inhibitors: a tale of 9 drugs.
    Giugliano D; Esposito K
    Cardiovasc Diabetol; 2019 Jul; 18(1):94. PubMed ID: 31337395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of heart failure development in type 2 diabetes: a practical approach.
    Verma S; Sharma A; Kanumilli N; Butler J
    Curr Opin Cardiol; 2019 Sep; 34(5):578-583. PubMed ID: 31219877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
    Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
    Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
    Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
    [No Abstract]   [Full Text] [Related]  

  • 56. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
    Imprialos K; Stavropoulos K; Papademetriou V
    Heart Fail Clin; 2019 Oct; 15(4):519-530. PubMed ID: 31472887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
    Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.